APEC health initiatives move forward amid limited progress elsewhere
This article was originally published in Scrip
This weekend's Asia Pacific Economic Cooperation (APEC) summit in Japan may have been criticised for a lack of substantive overall progress, but the grouping has at least agreed to continue moving forward in areas relevant to health and the pharma industry.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.